ADMA Biologics announces $200 million capital return initiative
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Should l Buy ADMA?
Source: seekingalpha
ADMA Biologics Inc. saw its stock price drop after crossing below the 5-day SMA, reflecting broader market weakness with the Nasdaq-100 down 1.30% and the S&P 500 down 1.27%.
The company announced a capital return initiative targeting approximately $200 million in 2026, including a $125 million accelerated share repurchase agreement with JPMorgan, which underscores its commitment to enhancing shareholder value. This initiative follows a disciplined buyback program that has already seen ADMA repurchase around $160 million of its common stock since May 2025, indicating confidence in its stock price and future growth prospects.
Despite the current stock price decline, ADMA's strong financial performance in 2025, with a 20% revenue increase and a 40% rise in adjusted EBITDA, positions the company well for future success, particularly with its ASCENIV product driving margin expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm has announced an investigation into ADMA Biologics for potentially issuing materially misleading business information, which, if substantiated, could severely impact the company's reputation and stock price.
- Stock Price Plunge: On March 24, 2026, ADMA Biologics shares fell by 16.6% after short seller Culper Research alleged the company engaged in channel stuffing to inflate revenue, highlighting serious market concerns regarding the company's financial transparency.
- Class Action Preparation: Rosen Law Firm is preparing a class action to seek recovery for investor losses, allowing investors to participate through a contingency fee arrangement, indicating the firm's commitment to protecting investor rights.
- Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and expertise in the securities litigation field.
See More
ADMA Biologics Shares Plunge 16% Amid Investigation
- Stock Price Drop: ADMA Biologics saw its shares plummet over 16% on March 24, 2026, following a report by Culper Research that revealed issues of channel stuffing and undisclosed related party distributors, severely undermining investor confidence.
- Investigation Launched: National shareholder rights firm Hagens Berman has initiated an investigation into ADMA to determine if the company violated federal securities laws, particularly regarding compliance in financial reporting, urging investors who suffered significant losses to submit their information to assist in the inquiry.
- Financial Transparency Issues: Culper Research highlighted a dramatic increase in ADMA's days sales outstanding (DSO), which surged from 43 days in 2024 to 113 days in 2025, indicating that the company may have inflated revenues by extending payment terms and offering rebates, thereby compromising financial transparency and investor trust.
- Analyst Downgrade: The market reacted swiftly, prompting a prominent analyst to downgrade ADMA's rating from overweight to neutral, reflecting growing concerns about the company's financial health and pessimistic expectations for future performance.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Rationale: Bleichmar Fonti & Auld LLP is investigating ADMA Biologics for potentially misleading investors with a reported 20% revenue growth in 2025, which may have been artificially inflated through channel stuffing, raising serious concerns about the company's financial transparency.
- Channel Stuffing Allegations: A report by Culper Research claims that ADMA Biologics incentivized a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allegedly allowed the company to report growth that did not exist; without this scheme, revenue would have declined by 3%, significantly undermining investor confidence.
- Stock Price Plunge: Following these allegations, ADMA Biologics' stock price plummeted by 29% over two trading days, from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, indicating extreme market pessimism regarding the company's future prospects.
- Legal Options for Investors: Investors are encouraged to submit their information to BFA for potential legal recourse, with the firm offering contingency fee arrangements, highlighting a commitment to protecting investor rights while potentially impacting ADMA's reputation and future financing capabilities.
See More
ADMA Biologics Under Investigation for Securities Fraud
- Investigation Background: Leading securities law firm Bleichmar Fonti & Auld LLP is investigating ADMA Biologics for potential violations of federal securities laws, particularly regarding the authenticity of its reported 20% revenue growth in 2025.
- Revenue Growth Concerns: A report by Culper Research claims that ADMA Biologics engaged in channel stuffing by inducing distributors to stockpile ASCENIV, masking actual demand declines, and that without this scheme, the company would have faced a 3% revenue decline in 2025.
- Stock Price Plunge: The investigation news led to a 29% drop in ADMA Biologics' stock price over two days, falling from $13.59 per share on March 23 to $9.63 on March 25, reflecting market concerns over its financial transparency.
- Legal Options for Investors: Investors are encouraged to submit their information for legal assistance, with BFA offering representation on a contingency fee basis, highlighting its commitment to protecting investor rights.
See More
ADMA Biologics Faces Legal Investigation
- Legal Investigation Launched: Bragar Eagel & Squire, P.C. is investigating ADMA Biologics, Inc. for potential violations of federal securities laws and other unlawful business practices, indicating serious concerns about the company's compliance.
- Short Report Allegations: A short report published by Culper Research on March 24, 2026, claims that ADMA's reported growth is fictional, driven by undisclosed channel stuffing, estimating a 3% revenue decline in 2025 instead of the reported 20% growth, revealing potential financial fraud risks.
- Significant Stock Price Drop: Following the release of the short report, ADMA's stock price fell by $2.26, or 16.63%, closing at $11.33 per share, reflecting market concerns over the company's financial health and potentially diminishing investor confidence.
- Investor Rights Protection: Bragar Eagel & Squire is reaching out to affected investors for legal consultations, emphasizing the importance of seeking legal support when facing potential losses, which may influence future investment decisions.
See More
ADMA Biologics Under Investigation for Securities Violations
- Channel Stuffing Allegations: A report by Culper Research revealed that ADMA Biologics allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, resulting in a reported 20% growth that masked a real decline of 3% in 2025.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating potential violations of federal securities laws by ADMA Biologics, which could expose the company to significant legal liabilities and financial repercussions if proven true.
- Investor Losses: The report indicates that investors who suffered losses exceeding $50,000 in ADMA Biologics securities may be eligible to participate in litigation, which could adversely affect the company's reputation and lead to a decline in stock price.
- Market Reaction Anticipated: Due to the allegations of financial misconduct, market confidence in ADMA Biologics may be shaken, prompting investors to closely monitor the investigation's progress and its potential impact on the company's future performance.
See More
ADMA Biologics Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm has announced an investigation into ADMA Biologics for potentially issuing materially misleading business information, which, if substantiated, could severely impact the company's reputation and stock price.
- Stock Price Plunge: On March 24, 2026, ADMA Biologics shares fell by 16.6% after short seller Culper Research alleged the company engaged in channel stuffing to inflate revenue, highlighting serious market concerns regarding the company's financial transparency.
- Class Action Preparation: Rosen Law Firm is preparing a class action to seek recovery for investor losses, allowing investors to participate through a contingency fee arrangement, indicating the firm's commitment to protecting investor rights.
- Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong track record and expertise in the securities litigation field.
See More
ADMA Biologics Shares Plunge 16% Amid Investigation
- Stock Price Drop: ADMA Biologics saw its shares plummet over 16% on March 24, 2026, following a report by Culper Research that revealed issues of channel stuffing and undisclosed related party distributors, severely undermining investor confidence.
- Investigation Launched: National shareholder rights firm Hagens Berman has initiated an investigation into ADMA to determine if the company violated federal securities laws, particularly regarding compliance in financial reporting, urging investors who suffered significant losses to submit their information to assist in the inquiry.
- Financial Transparency Issues: Culper Research highlighted a dramatic increase in ADMA's days sales outstanding (DSO), which surged from 43 days in 2024 to 113 days in 2025, indicating that the company may have inflated revenues by extending payment terms and offering rebates, thereby compromising financial transparency and investor trust.
- Analyst Downgrade: The market reacted swiftly, prompting a prominent analyst to downgrade ADMA's rating from overweight to neutral, reflecting growing concerns about the company's financial health and pessimistic expectations for future performance.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Rationale: Bleichmar Fonti & Auld LLP is investigating ADMA Biologics for potentially misleading investors with a reported 20% revenue growth in 2025, which may have been artificially inflated through channel stuffing, raising serious concerns about the company's financial transparency.
- Channel Stuffing Allegations: A report by Culper Research claims that ADMA Biologics incentivized a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allegedly allowed the company to report growth that did not exist; without this scheme, revenue would have declined by 3%, significantly undermining investor confidence.
- Stock Price Plunge: Following these allegations, ADMA Biologics' stock price plummeted by 29% over two trading days, from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, indicating extreme market pessimism regarding the company's future prospects.
- Legal Options for Investors: Investors are encouraged to submit their information to BFA for potential legal recourse, with the firm offering contingency fee arrangements, highlighting a commitment to protecting investor rights while potentially impacting ADMA's reputation and future financing capabilities.
See More
ADMA Biologics Under Investigation for Securities Fraud
- Investigation Background: Leading securities law firm Bleichmar Fonti & Auld LLP is investigating ADMA Biologics for potential violations of federal securities laws, particularly regarding the authenticity of its reported 20% revenue growth in 2025.
- Revenue Growth Concerns: A report by Culper Research claims that ADMA Biologics engaged in channel stuffing by inducing distributors to stockpile ASCENIV, masking actual demand declines, and that without this scheme, the company would have faced a 3% revenue decline in 2025.
- Stock Price Plunge: The investigation news led to a 29% drop in ADMA Biologics' stock price over two days, falling from $13.59 per share on March 23 to $9.63 on March 25, reflecting market concerns over its financial transparency.
- Legal Options for Investors: Investors are encouraged to submit their information for legal assistance, with BFA offering representation on a contingency fee basis, highlighting its commitment to protecting investor rights.
See More
ADMA Biologics Faces Legal Investigation
- Legal Investigation Launched: Bragar Eagel & Squire, P.C. is investigating ADMA Biologics, Inc. for potential violations of federal securities laws and other unlawful business practices, indicating serious concerns about the company's compliance.
- Short Report Allegations: A short report published by Culper Research on March 24, 2026, claims that ADMA's reported growth is fictional, driven by undisclosed channel stuffing, estimating a 3% revenue decline in 2025 instead of the reported 20% growth, revealing potential financial fraud risks.
- Significant Stock Price Drop: Following the release of the short report, ADMA's stock price fell by $2.26, or 16.63%, closing at $11.33 per share, reflecting market concerns over the company's financial health and potentially diminishing investor confidence.
- Investor Rights Protection: Bragar Eagel & Squire is reaching out to affected investors for legal consultations, emphasizing the importance of seeking legal support when facing potential losses, which may influence future investment decisions.
See More
ADMA Biologics Under Investigation for Securities Violations
- Channel Stuffing Allegations: A report by Culper Research revealed that ADMA Biologics allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, resulting in a reported 20% growth that masked a real decline of 3% in 2025.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating potential violations of federal securities laws by ADMA Biologics, which could expose the company to significant legal liabilities and financial repercussions if proven true.
- Investor Losses: The report indicates that investors who suffered losses exceeding $50,000 in ADMA Biologics securities may be eligible to participate in litigation, which could adversely affect the company's reputation and lead to a decline in stock price.
- Market Reaction Anticipated: Due to the allegations of financial misconduct, market confidence in ADMA Biologics may be shaken, prompting investors to closely monitor the investigation's progress and its potential impact on the company's future performance.
See More
